| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Establishment Labs Holdings Inc.$87.21
+0.2 (+0.23%)
D 27Pipeline Score MedTech · Commercial
Market Cap
2.12 B
EPS
-1.48
P/E Ratio
-
Value Trade
19.89 M
SEC Financials
Q1 2026Dilution Risk
Revenue
59.88 M
R&D Expenses
5.24 M
Operating CF
-4.31 M
Total Assets
351.04 M
Total Liabilities
336.25 M
Equity
14.78 M
D/E Ratio
12,345
5.2 %
Week
10.6 %
1 Month
-3.3 %
3 Month
8.98 %
6 Month
-3.33 %
5 Year
177.65 %
All Time
Cash Data
Cash Position
68.10 M
Monthly Burn
1.44 M
Runway
46.1 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
789.12 K
52 Week Range
33.35 - 83.31
% held by Insiders
8.52 %
% held by Institutions
99.13 %
Enterprise Value
2.32 B
Total Shares
29.40 M
Short %
15.87 %
Float Shares
24.10 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D27
Pipeline Score $73M
Pipeline ValueValuation Signal
1
Drugs Scored0.0x
rNPV / MCap Top 30%
Small Cap (rank 634 of 905)
Percentile RankEstablishment Labs Holdings Inc. faces pipeline headwinds (27/100), with $112M risk-adjusted pipeline value, led by Expanded autologous ASCs in Peripheral Vascular Diseases (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expanded autologous ASCs Monoclonal antibody | Peripheral Vascular Diseases | Phase 1 | NCT01211028 | 26% | $112M | COMPLETED | 13 | - | - | Jul 1, 2012 | - | May 11, 2017 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ESTA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ESTA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ESTA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ESTA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ESTA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ESTA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ESTAEstablishment Labs Reports First Quarter 2026 Financial Results
Establishment Labs Holdings Inc. reported a 44.7% increase in revenue for Q1 2026, reaching $59.9 million. The company raised its annual revenue guidance due to strong sales in the U.S. and internationally. Notably, adjusted EBITDA was positive for the third consecutive quarter, reflecting improved operational efficiency. However, the company still reported a net loss of $13.4 million, despite a significant reduction from the previous year.
Read more →ESTAInvestor Media Contact Malavika William mwilliam establishmentlabs.com Establishment Labs Reports First Quarter 2026 Financial Results
Establishment Labs Holdings Inc. reported robust financial results for the first quarter of 2026, showcasing a revenue increase of 44.7% to $59.9 million. The company also demonstrated improved operational efficiency with a reduction in losses and the achievement of positive adjusted EBITDA for the third consecutive quarter. Management raised its full-year guidance, anticipating continued growth driven by the successful launch of its minimally invasive platform. The company maintains a strong cash position of $68.1 million as of the quarter's end.
Read more →ESTAEstablishment Labs® Refinances Credit Facility
Establishment Labs Holdings Inc. has announced a $300 million senior secured term loan facility with Oaktree Capital Management. This refinancing of existing debt provides the company with additional capital to support its ongoing initiatives in women's health, particularly in breast aesthetics and reconstruction. The move is expected to enhance the company's financial position.
Read more →ESTAEstablishment Labs® to Announce First Quarter 2026 Financial Results on May 6
Establishment Labs Holdings Inc. is set to announce its financial results for Q1 2026 on May 6, 2026. The announcement will occur before market opening, followed by a conference call at 8:30 am ET. This event highlights the company's commitment to transparency and investor relations.
Read more →ESTAEstablishment Labs® Surpasses More Than Five Million Motiva® Devices in Market
Establishment Labs has announced that it has surpassed five million Motiva devices sold in the market. This achievement highlights the company's growth and the increasing acceptance of its innovative products. The milestone indicates a robust demand for Motiva devices, which are designed for aesthetic and reconstructive purposes.
Read more →ESTAEstablishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
Establishment Labs Holdings Inc. reported strong financial results for Q4 2025, with total revenue reaching $64.6 million, up from $44.5 million in Q4 2024. The company highlighted robust demand for its Preservé product and anticipates continued growth, projecting over 25% topline growth for 2026 and 2027. Despite a net loss of $3.9 million, the company achieved positive adjusted EBITDA and is on track for positive cash flow in 2026.
Read more →ESTAEstablishment Labs Announces Leadership Transition to Support Next Phase of Growth
Establishment Labs Holdings Inc. announced a leadership transition, promoting Cassandra Harris to CFO while Raj Denhoy shifts to Senior VP of Global Strategy. This change is intended to support the company's growth initiatives and operational momentum. Harris, a seasoned financial executive, expressed her commitment to advancing the company's mission in women's health.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
Establishment Labs Holdings Inc. reported strong financial results for the fourth quarter and full year 2025, with a 45.2% increase in quarterly revenue, reaching $64.6 million. The company also provided optimistic guidance for 2026, projecting revenue of between $264 million and $266 million, reflecting a growth rate of 25.1% to 26.0%. While the adjusted EBITDA showed significant improvement at $5.5 million, the company still posted a net loss from operations of $3.9 million, although this marked a considerable reduction from $18.7 million a year prior. Establishment Labs continues to emphasize its strong market demand and expansion into new consumer demographics.
Read more →ESTAEstablishment Labs to Present at TD Cowen's 46th Annual Health Care Conference
Establishment Labs Holdings Inc. will present at TD Cowen's 46th Annual Health Care Conference on March 2, 2026. CEO Peter Caldini and CFO Raj Denhoy will participate in a fireside chat, which will be available via live webcast. The company is recognized for its commitment to women's health through innovative breast aesthetic and reconstruction solutions.
Read more →ESTAEstablishment Labs to Announce Fourth Quarter 2025 Financial Results on February 24
Establishment Labs Holdings Inc. plans to announce its financial results for Q4 2025 on February 24, 2026, before the market opens. A conference call will follow at 8:30 am ET to discuss these results. The company focuses on women's health, offering advanced solutions in breast aesthetics and reconstruction.
Read more →ESTADocument
Document
Read more →ESTAEstablishment Labs to Present at 44th Annual J.P. Morgan Healthcare Conference
Establishment Labs Holdings Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Peter Caldini and CFO Raj Denhoy will discuss the company's advancements in women's health and breast aesthetics. A live webcast will be available on the investor relations website, with archived versions to follow.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 Revenue for the quar
Establishment Labs announced preliminary unaudited financial results for the fourth quarter and fiscal year 2025, expecting revenues between $64.0 million and $65.0 million for the quarter. For the full year, the company anticipates revenues in the range of $210.5 million to $211.5 million, indicating a growth of about 27% compared to 2024. The company also reported an increase in cash position and expressed optimism for continued growth into 2026, although the results remain subject to audit.
Read more →ESTAEstablishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction
Establishment Labs has submitted its Motiva implants for FDA approval in primary and revision breast reconstruction. This follows their previous approval for breast augmentation in 2024. The implants are designed to improve patient outcomes with innovative features that adapt to body movements. The company aims to enhance women's health and wellness through advanced technology in breast reconstruction.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Second Quarter 2025 Financial Results
Establishment Labs Holdings Inc. announced financial results for Q2 2025, reporting a revenue of $51.3 million, a 16.3% increase year-over-year. The company raised its revenue guidance for 2025 to between $208 million and $212 million, driven by robust Motiva sales in the U.S. Despite these gains, the company reported a loss from operations of $14.1 million, larger than in the same quarter last year. CEO Peter Caldini emphasized ongoing sales momentum and growth prospects in the U.S. and internationally.
Read more →ESTAinvestorsday Investor Day Welcome Agenda Topic Presenter/Moderator Welcome; Logistics; Agenda Raj Denhoy Corporate Overview Peter Caldini Motiva USA Business Updates Jeff Ehrhardt US Breast Aesthetic - Panel Ben Newcott
Establishment Labs held its Investors' Day, revealing ambitious goals and updates regarding its business and product pipeline. The company anticipates significant revenue growth in the U.S., projecting targets between $205 million and $210 million for the upcoming year. The company is also focused on increasing its market presence in Europe and Latin America through new product launches. Additionally, Establishment Labs aims to improve operational efficiency and expects to achieve positive EBITDA by 2025, marking a pathway to becoming a leader in breast aesthetics and reconstruction.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports First Quarter 2025 Financial Results
Establishment Labs Holdings Inc. reported its financial results for the first quarter of 2025, showing worldwide revenue of $41.4 million and maintaining revenue guidance between $205 million and $210 million for the year. The company's gross margin increased to 67.2%, reflecting improved operational efficiency. However, the net loss widened to $20.7 million, and operating expenses significantly rose, indicating ongoing financial challenges. CEO Peter Caldini expressed optimism regarding future profitability aligned with the continued success of the Motiva platform in the U.S. market.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Provides Preliminary First Quarter Results and Announces an Investor Day on June 12
Establishment Labs Holdings Inc. has reported preliminary first quarter sales for 2025 that are projected to reach approximately $41.4 million, bolstered by significant growth from the Motiva product line. The company plans to host an investor day on June 12, focusing on its product launch and future innovations. Interim CEO Peter Caldini highlighted that the growth trajectory remains strong, with average daily orders exceeding 100 in March. Establishment Labs anticipates a positive EBITDA and cash flow by 2025 and 2026, respectively.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Fourth Quarter and Full Year 2024 Financial Results and Reaffirms 2025 Guidance
Establishment Labs Holdings Inc. has reported its financial results for the fourth quarter and full year of 2024, highlighting a revenue of $44.5 million. The company has reaffirmed its 2025 revenue guidance, anticipating an increase of 23% to 26% over 2024, largely driven by the launch of Motiva Implants in the U.S. market. While the company reported a reduced net loss of $18.7 million, it also noted an increase in operating expenses as part of its growth strategy. The CEO expressed optimism about meeting and surpassing sales expectations, supporting the company’s goal of sustainable profitability.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Announces CEO Transition Peter Caldini to become Interim CEO effective
Establishment Labs Holdings Inc. announced that Peter Caldini will become the Interim CEO effective March 1, 2025, after Juan Jose Chac n-Quir s retires. Chac n-Quir s will remain with the company as a board member and advisor, facilitating growth in breast aesthetics and reconstruction technologies. The company also reported preliminary unaudited fourth quarter revenue, projecting 2024 revenue to be between $166 million and $166.5 million. Establishment Labs is committed to innovation in women's health and wellness regarding breast aesthetics.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Announces $50 million Registered Direct Offering
Establishment Labs Holdings Inc. has announced a registered direct offering to raise approximately $50 million by selling common shares and pre-funded warrants. The offering involves 765,696 common shares at $45.71 per share, along with additional warrants, and is expected to close on November 12, 2024. The proceeds are intended for various corporate purposes, including research, marketing, and general administrative expenses. This move highlights the company’s focus on funding its innovative solutions in women's health.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Second Quarter 2024 Financial Results
Establishment Labs Holdings Inc. reported its financial results for the second quarter of 2024, showcasing a revenue of $44.1 million, with an outlook projecting 2024 revenue between $174 million and $184 million. The company noted a gross profit margin improvement to 65.6% and a reduction in operational losses compared to the previous year. A pivotal moment is anticipated with the expected FDA approval of its Motiva Implants, which could establish new standards in breast aesthetics in the U.S. market. Despite some challenges, including a slight increase in net loss, the company expressed optimism about its path to growth and market leadership.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports First Quarter 2024 Financial Results
Establishment Labs Holdings Inc. reported its financial results for the first quarter of 2024, revealing a revenue of $37.2 million. The company maintains a positive revenue guidance of $174 million to $184 million for the year, driven by expected improvements in market demand and the anticipated launch of Motiva Implants in the U.S. Despite the positive outlook, the company reported an increased net loss compared to the previous year. The firm continues to make strides in regulatory approvals and product launches globally.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance
Establishment Labs Holdings Inc. reported its financial results for Q4 and full year 2023, revealing a revenue of $31.6 million for Q4 and a projected revenue increase of 5% to 11% for 2024. The company incurred a net loss of $22.1 million, up from $13.2 million from the previous year, while also noting a significant adjustment in its credit facility. The launch of Motiva Implants in China and a first U.S. procedure indicates significant market expansion, although losses in adjusted EBITDA raise concerns. The company aims for positive adjusted EBITDA later this year and plans to achieve cash flow positivity by 2025.
Read more →ESTAESTABLISHMENT LABS ANNOUNCES $50 MILLION PRIVATE PLACEMENT AND PRELIMINARY UNAUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2023 JANUARY 9, 2024 NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings I
Establishment Labs announced a $50 million private placement and preliminary unaudited financial results for Q4 and fiscal year 2023. The company expects Q4 revenue between $31.4 million and $31.8 million, contributing to an annual revenue estimate of $165.0 million to $165.4 million. Despite a significant reduction in cash reserves, the CEO highlighted a recovery in market demand and aims for positive cash flow by 2025. The private placement is set to close on January 12, 2024, and will support working capital needs.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Third Quarter 2023 Financial Results
Establishment Labs Holdings Inc. announced its financial results for the third quarter of 2023, reporting a slight revenue increase of 0.8% year-over-year to $38.5 million, but also a net loss rising to $29.3 million. The company's revenue guidance has been adjusted downwards due to declining demand for breast procedures, particularly affecting forecasts related to China. However, management remains optimistic about future growth, especially with the recent U.S. FDA clearance of the Motiva Flora SmoothSilk Tissue Expander and the ongoing expansion of their product portfolio.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Record Second Quarter 2023 Financial Results
Establishment Labs Holdings Inc. reported record financial results for the second quarter of 2023, achieving $48.6 million in revenue, which is an 18% increase from the previous year. Despite the revenue growth, the company's operating losses increased to $13.7 million due to higher expenses related to growth initiatives. The company has a cash balance of $90.2 million and has opened a new facility aimed at enhancing its R&D and manufacturing capabilities. Establishment Labs also continues to make advancements with its Mia Femtech product line and regulatory approvals.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Record First Quarter 2023 Financial Results
Establishment Labs (NASDAQ: ESTA) reported record financial results for the first quarter of 2023, achieving a revenue of $46.5 million, a 21% increase year-over-year. Despite the positive revenue growth, the company experienced an increase in operational losses, now totaling $8.2 million, and a net loss of $11.9 million. The firm successfully launched its Mia Femtech product in Japan, raised substantial capital through a share offering, and is advancing its growth initiatives globally. The company continues to strengthen its market position with ongoing partnerships and strategic plans, including new manufacturing capabilities.
Read more →ESTAEstablishment Labs Announces Preliminary Unaudited Results for First Quarter 2023
Establishment Labs Holdings Inc. announced preliminary unaudited results for Q1 2023, indicating an expected revenue of about $46.5 million, up from $38.5 million in the previous year. The company's cash balance is projected to be approximately $42.8 million. However, these results are not final and may change upon audit, and there is a significant outstanding amount under its credit facility. Risks relating to future performance and industry competition may affect the company's actual outcomes.
Read more →ESTAEstablishment Labs Notes Presentation of 3-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2023 New York, NY
Establishment Labs Holdings Inc. presented three-year results from the Motiva U.S. IDE study at The Aesthetic Meeting 2023, showing encouraging data. The study reported a high patient compliance of 92.4% among 451 primary augmentation patients, with low complication rates, particularly no increase in significant issues such as capsular contracture. The findings will support the company's efforts to secure FDA approval for the Motiva implants, which promise a new standard in breast aesthetics for women in the U.S.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Submits Module Four to U.S. FDA for Premarket Approval of Motiva and Reports Record Fourth Quarter and Full Ye
Establishment Labs Holdings Inc. (NASDAQ ESTA) has submitted the fourth and final module of its premarket approval application for Motiva Implants to the U.S. FDA. The company reported a record fourth quarter with sales reaching $43.8 million, marking a 24.1% increase compared to the previous year. Additionally, it announced guidance for 2023 revenue between $200 million and $210 million, reflecting expected growth. Despite a net loss of $13.6 million in the fourth quarter, the company maintains a robust cash position of $66.4 million and a positive outlook for the upcoming year.
Read more →ESTApresentationmateria Founder & CEO Establishment Labs JUAN JOSÉ CHACÓN-QUIRÓS JANUARY 12th, 2023 41 Annual J.P. Morgan Healthcare Conference st FORWARD LOOKING STATEMENTS AND OTHER LEGAL MATTERS This
Establishment Labs' Founder and CEO Juan José Chacón-Quiroz presented at the J.P. Morgan Healthcare Conference, discussing the company's forward-looking strategy and innovations in women's health. The presentation highlights successes in the breast implant market, including the adoption of Motiva Implants and new technologies aimed at improving product safety and efficacy. However, the company also acknowledges inherent risks related to regulatory approvals and market uncertainties, advising investors to be cautious regarding projections.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Announces Preliminary Unaudited Revenue for Fourth Quarter and Fiscal Year 2022 Fourth-quarter revenue is expe
Establishment Labs Holdings Inc. announced its preliminary unaudited revenue figures for the fourth quarter and fiscal year 2022. The company expects fourth-quarter revenue between $43.3 million and $44.3 million, representing a 23% to 25% growth over the previous year. For the fiscal year, revenue is predicted to be between $161.2 million and $162.2 million, marking a 27% to 28% increase. The CEO highlighted significant growth in constant currency terms and mentioned future product expansions to enhance market reach.
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Third Quarter 2022 Financial Results
Coyol Free Zone Business Park Building, 4 th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.1 Establishment Labs Reports Third Quarter 2022 Financial Results SANTA BARBARA, Calif., November 7, 2022 --
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Record Second Quarter 2022 Financial Results
Coyol Free Zone Business Park Building, 4 th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.1 Establishment Labs Reports Record Second Quarter 2022 Financial Results SANTA BARBARA, Calif., August 8, 20
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Record First Quarter 2022 Financial Results
Coyol Free Zone Business Park Building, 4 th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.1 Establishment Labs Reports Record First Quarter 2022 Financial Results SANTA BARBARA, Calif., May 9, 2022 -
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Fourth Quarter and Full Year 2021 Financial Results Record Fourth Quarter Revenue of $35.3 Million
Coyol Free Zone Business Park Building, 4 th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.1 Establishment Labs Reports Fourth Quarter and Full Year 2021 Financial Results Record Fourth Quarter Revenue
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Announces Preliminary Fourth Quarter and Fiscal Year 2021 Revenue Fourth quarter revenue expected to be in the
Coyol Free Zone Business Park Building, 4 th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.1 Establishment Labs Announces Preliminary Fourth Quarter and Fiscal Year 2021 Revenue Fourth quarter revenue
Read more →ESTAInvestor Media Contact Raj Denhoy 415-828-1044 rdenhoy establishmentlabs.com Establishment Labs Announces Appointment of Raj Denhoy as Chief Financial Officer
PRESS RELEASE Investor Media Contact Raj Denhoy 415-828-1044 rdenhoy establishmentlabs.com Establishment Labs Announces Appointment of Raj Denhoy as Chief Financial Officer SANTA BARBARA, Calif., December 13, 2021 -- Establishment Labs Holdings Inc. (NASDAQ ESTA), a global
Read more →ESTAInvestor Media Contact Raj Denhoy 415-828-1044 rdenhoy establishmentlabs.com Establishment Labs Announces Appointment of Leslie Gillin to Board of Directors
PRESS RELEASE Investor Media Contact Raj Denhoy 415-828-1044 rdenhoy establishmentlabs.com Establishment Labs Announces Appointment of Leslie Gillin to Board of Directors SANTA BARBARA, Calif., December 10, 2021 -- Establishment Labs Holdings Inc. (NASDAQ ESTA), a global me
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Third Quarter 2021 Financial Results and Raises Full Year Guidance
Coyol Free Zone Business Park Building, 4 th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.1 Establishment Labs Reports Third Quarter 2021 Financial Results and Raises Full Year Guidance SANTA BARBAR
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Record Second Quarter 2021 Financial Results and Raises Full Year Guidance
Coyol Free Zone Business Park Building, 4 th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.1 Establishment Labs Reports Record Second Quarter 2021 Financial Results and Raises Full Year Guidance SANTA
Read more →ESTAInvestor Media Contact Raj Denhoy 415-828-1044 rdenhoy establishmentlabs.com Establishment Labs Announces Appointment of Ann Custin and Bryan Slotkin to Board of Directors
PRESS RELEASE Investor Media Contact Raj Denhoy 415-828-1044 rdenhoy establishmentlabs.com Establishment Labs Announces Appointment of Ann Custin and Bryan Slotkin to Board of Directors SANTA BARBARA, Calif., July 15, 2021 -- Establishment Labs Holdings Inc. (NASDAQ ESTA),
Read more →ESTAInvestor Media Contact Raj Denhoy 415-828-1044 rdenhoy establishmentlabs.com Establishment Labs Announces Departure of CFO and Appointment of Raj Denhoy as Interim CFO Company also announces preliminary sec
PRESS RELEASE Investor Media Contact Raj Denhoy 415-828-1044 rdenhoy establishmentlabs.com Establishment Labs Announces Departure of CFO and Appointment of Raj Denhoy as Interim CFO Company also announces preliminary second quarter 2021 revenue of $31 million to $32 million
Read more →ESTAEstablishment Labs Announces Pratip Dastidar Has Joined the Company as Head of Global Operations
Establishment Labs Announces Pratip Dastidar Has Joined the Company as Head of Global Operations SANTA BARBARA, Calif., May 18, 2021 -- Establishment Labs Holdings Inc. (NASDAQ ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Record First Quarter 2021 Financial Results and Raises Full Year Guidance
Establishment Labs Reports Record First Quarter 2021 Financial Results and Raises Full Year Guidance SANTA BARBARA, Calif., May 5, 2021 -- Establishment Labs Holdings Inc. (NASDAQ ESTA), a medical technology company focused on women's health, initially in the breast aesthetics a
Read more →ESTAInvestor Media Contact Raj Denhoy 415 828-1044 rdenhoy establishmentlabs.com Establishment Labs Reports Fourth Quarter and Full Year 2020 Financial Results Record Fourth Quarter Revenue of $27.0 Million
Establishment Labs Reports Fourth Quarter and Full Year 2020 Financial Results Record Fourth Quarter Revenue of $27.0 Million SANTA BARBARA, Calif., March 10, 2021 -- Establishment Labs Holdings Inc. (NASDAQ ESTA), a medical technology company focused on women's health, initiall
Read more →ESTAEstablishment Labs Hosts Investor Event for its Motiva MIA System for Minimally Invasive Augmentation Minimally Invasive creates a new product category in breast aesthetics with a total addressable market of $4-5 billion
Establishment Labs Hosts Investor Event for its Motiva MIA System for Minimally Invasive Augmentation Minimally Invasive creates a new product category in breast aesthetics with a total addressable market of $4-5 billion Clinical study shows significant benefits compared to tra
Read more →ESTAEstablishment Labs Reports Preliminary Results for Fourth Quarter and Fiscal Year 2020 Preliminary Revenue of $26.5 million to $27.5 million for the 4th Quarter, and $84.2 million to $85.2 million for Fiscal Year 2020 St
Establishment Labs Reports Preliminary Results for Fourth Quarter and Fiscal Year 2020 Preliminary Revenue of $26.5 million to $27.5 million for the 4th Quarter, and $84.2 million to $85.2 million for Fiscal Year 2020 Strong Performance Throughout Europe and Rebound to Pre-Pand
Read more →ESTAMotiva Ergonomix2 Platform and Motiva Mia Implant Receive CE Mark Commercial Launch of Ergonomix2 Planned for 2021 Approval Accelerates Path to Europe for Motiva Mia Pre-Commercial European Mia Procedures to Begin in Sec
Motiva Ergonomix2 Platform and Motiva Mia Implant Receive CE Mark Commercial Launch of Ergonomix2 Planned for 2021 Approval Accelerates Path to Europe for Motiva Mia Pre-Commercial European Mia Procedures to Begin in Second Half of 2021 SANTA BARBARA, Calif., Dec. 14, 2020 --
Read more →ESTAEstablishment Labs Reports Preliminary Third Quarter Revenue and Cash Balance $22 million to $23 million 3rd Quarter Preliminary Revenue Cash Balance at
Establishment Labs Reports Preliminary Third Quarter Revenue and Cash Balance $22 million to $23 million 3rd Quarter Preliminary Revenue Cash Balance at September 30, 2020 an Estimated $81.0 million Company to Announce Full 3rd Quarter Results on November 9 SANTA BARBARA, Cal
Read more →ESTAEstablishment Labs Finalizes Distribution Agreement with Puregraft
Establishment Labs Finalizes Distribution Agreement with Puregraft LLC SANTA BARBARA, Calif., September 25, 2020 - Establishment Labs Holdings Inc. (NASDAQ ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market
Read more →ESTAEstablishment Labs Announces Transition to a Direct Sales Force in Italy
Establishment Labs Announces Transition to a Direct Sales Force in Italy NEW YORK, Thursday, August 6, 2020 -- Establishment Labs Holdings Inc. (NASDAQ ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, to
Read more →ESTAEstablishment Labs Reports Record First Quarter 2020 Financial Results
Establishment Labs Reports Record First Quarter 2020 Financial Results NEW YORK, May 7, 2020 -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced
Read more →ESTAEstablishment Labs Reports Fourth Quarter and Full Year 2019 Financial Results
Establishment Labs Reports Fourth Quarter and Full Year 2019 Financial Results NEW YORK -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced its f
Read more →ESTAEstablishment Labs Reports Third Quarter 2019 Financial Results
Establishment Labs Reports Third Quarter 2019 Financial Results NEW YORK -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced its financial result
Read more →ESTAEstablishment Labs Reports Second Quarter 2019 Financial Results
Establishment Labs Reports Second Quarter 2019 Financial Results NEW YORK -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced its financial resul
Read more →ESTAestainvestordaysbtmjune2 Roberto de Mezerville Chief Technology Officer INVESTOR DAY - COSTA RICA | JUNE 18TH | RDI Since 2004 - Motiva Evolution Company confidential. Proprietary information. Do not distribute. Motiva I
Roberto de Mezerville Chief Technology Officer INVESTOR DAY - COSTA RICA | JUNE 18TH | RDI Since 2004 - Motiva Evolution Company confidential. Proprietary information. Do not distribute. Motiva Implants focus on customer needs - the Patient Aesthetics issues - reoperation Clini
Read more →ESTAEstablishment Labs Announces Additional Financing and Improved Terms with Amendment to Existing Credit Agreement
Establishment Labs Announces Additional Financing and Improved Terms with Amendment to Existing Credit Agreement NEW YORK, N.Y., June 17, 2019 (GLOBE NEWSWIRE) - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially i
Read more →ESTAEstablishment Labs Announces Appointment of Lisa Gersh to Board of Directors
Establishment Labs Announces Appointment of Lisa Gersh to Board of Directors NEW YORK, N.Y., June 6, 2019 (GLOBE NEWSWIRE) - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruc
Read more →ESTAEstablishment Labs Reports First Quarter 2019 Financial Results
Establishment Labs Reports First Quarter 2019 Financial Results NEW YORK, N.Y., May 15, 2019 (GLOBE NEWSWIRE) - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market,
Read more →ESTAEstablishment Labs Reports Fourth Quarter and Full Year 2018 Financial Results
Establishment Labs Reports Fourth Quarter and Full Year 2018 Financial Results NEW YORK, Mar. 20, 2019 (GLOBE NEWSWIRE) - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstructio
Read more →ESTAEstablishment Labs Reports Third -Quarter 2018 Financial Results
Establishment Labs Reports Third-Quarter 2018 Financial Results NEW YORK, November 13, 2018 (GLOBE NEWSWIRE) - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthe
Read more →ESTAEstablishment Labs Announces Transition to a Direct Sales Force in Germany and Spain During its 4th Annual World Symposium on Ergonomic Implants
Establishment Labs Announces Transition to a Direct Sales Force in Germany and Spain During its 4th Annual World Symposium on Ergonomic Implants NEW YORK, October 4, 2018 (GLOBE NEWSWIRE) - Establishment Labs Holdings, Inc. (NASDAQ: ESTA), a medical technology company focused on
Read more →Competitive Position
How ESTA ranks across every disease it competes inCompetitive Position is a premium feature
See how ESTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial